Live Breaking News & Updates on Haren Phd

Respiratory syncytial virus (RSV) is the leading global cause of death in children under age 5 and lacks an effective vaccine. In a study from the Precision Vaccines Program at Boston Children's Hospital, a new vaccine formulation protected newborn mice against infection and evoked strong responses in immune cells from human newborns in the laboratory. Results were reported August 2 in Nature Communications. ....

United States , Francesco Borriello , Simon Van Haren , Barneys Graham , Hanno Steen , Emily Henderson , Van Haren , Dennis Christensen , Gabriel Pedersen , Precision Vaccines Program At Boston Children Hospital , Roche Ltd , Human Development , Nature Communications , Precision Vaccines Program , Sana Biotechnology Inc , National Institute Of Allergy , Melinda Gates Foundation , Merck Sharp Dohme Corp , Boston Children Hospital Department Of Pediatrics , Precision Vaccine Program , National Institute Of Child Health , Boston Children , Haren Phd , Study First Author , Ofer Levy , Statens Serum Institut ,